Physician profile
Khaled Mansour
NPI 1427281641
$3,765.56
in general payments reported to CMS, 2019-2025
24 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $107 · 2021: $396 · 2022: $669 · 2023: $251 · 2024: $1,123 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.66 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $770.57 | 2022-2025 | Avvigo Guidance System, Watchman Flx |
| Abiomed | $487.26 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $464.77 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $362.53 | 2022-2025 | Lifevest |
| Pfizer INC. | $248.02 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $188.80 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $184.82 | 2020-2023 | Brilinta |
| E.R. Squibb & Sons, L.L.C. | $158.79 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $148.62 | 2021-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $137.38 | 2021-2025 | |
| Amgen INC. | $121.43 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $101.26 | 2024 | Mitraclip |
| Actelion Pharmaceuticals US, INC. | $66.99 | 2023 | Opsumit, Uptravi |
| Shockwave Medical, INC | $63.01 | 2021 | |
| Alnylam Pharmaceuticals INC. | $62.42 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $41.35 | 2024 | |
| Amarin Pharma, INC. | $30.84 | 2021 | |
| Convatec INC. | $25.02 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.35 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.77 | 2024 | Jardiance |
| Esperion Therapeutics, INC. | $18.45 | 2024 | Nexletol |
| Abbvie INC. | $15.49 | 2022 | |
| Novo Nordisk INC | $14.41 | 2024 | Ozempic |
| Medicomp INC | $12.21 | 2024 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaled Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.